Filtered By:
Infectious Disease: COVID-19
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 54 results found since Jan 2013.
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research
Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies
ConclusionThis review summarizes modifiable factors for intervention (e.g. smoking, obesity and inflammatory factors) and proteomic signatures (e.g. OAS1 and IL-6) that could help identify drugs for treating COVID-19.
Source: International Journal of Epidemiology - April 20, 2022 Category: Epidemiology Source Type: research
Vitamin D and its possible relationship to neuroprotection in COVID-19: evidence in the literature
Curr Top Med Chem. 2022 Apr 1. doi: 10.2174/1568026622666220401140737. Online ahead of print.ABSTRACTVitamin D is a hormone involved in the regulation of important biological processes such as signal transduction, immune response, metabolic regulation and also in the nervous and vascular systems. To date, coronavirus disease 2019 (COVID-19) infection does not have a specific treatment, however various drugs have been proposed, including those that attenuate the intense inflammatory response and recently the use of vitamin D, in clinical trials, as part of the treatment of COVID-19 has provided promising results. It has bee...
Source: Current Topics in Medicinal Chemistry - April 3, 2022 Category: Chemistry Authors: Saray Quintero-Fabi án Cindy Bandala Luz Adriana Pichardo-Mac ías Itzel Jatziri Contreras-Garc ía Sa úl Gómez-Manzo Beatriz Hern ández-Ochoa Jos é Arturo Martínez-Orozco Iv án Ignacio-Mejía Noem í Cárdenas-Rodríguez Source Type: research
Anticoagulants for people hospitalised with COVID-19
CONCLUSIONS: When compared to a lower-dose regimen, higher-dose anticoagulants result in little to no difference in all-cause mortality and increase minor bleeding in people hospitalised with COVID-19 up to 30 days. Higher-dose anticoagulants possibly reduce pulmonary embolism, slightly increase major bleeding, may result in little to no difference in hospitalisation time, and may result in little to no difference in deep vein thrombosis, stroke, major adverse limb events, myocardial infarction, atrial fibrillation, or thrombocytopenia. Compared with no treatment, anticoagulants may reduce all-cause mortality but the evide...
Source: Cochrane Database of Systematic Reviews - March 4, 2022 Category: General Medicine Authors: Ronald Lg Flumignan Vinicius T Civile J éssica Dantas de Sá Tinôco Patricia If Pascoal Libnah L Areias Charbel F Matar Britta Tendal Virginia Fm Trevisani Álvaro N Atallah Luis Cu Nakano Source Type: research
2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
Thromb Haemost. 2021 Nov 13. doi: 10.1055/s-0041-1739411. Online ahead of print.ABSTRACTThe consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the...
Source: Thrombosis and Haemostasis - November 13, 2021 Category: Hematology Authors: Tze-Fan Chao Boyoung Joung Yoshihide Takahashi Toon Wei Lim Eue-Keun Choi Yi-Hsin Chan Yutao Guo Charn Sriratanasathavorn Seil Oh Ken Okumura Gregory Y H Lip Source Type: research
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Neurologic Manifestations of the Antiphospholipid Syndrome - an Update
Curr Neurol Neurosci Rep. 2021 Jun 14;21(8):41. doi: 10.1007/s11910-021-01124-z.ABSTRACTPURPOSE OF REVIEW: In recent years, the spectrum of neurological manifestations of antiphospholipid syndrome (APS) has been growing. We provide a critical review of the literature with special emphasis on presentation, proposed mechanisms of disease, and treatment of neurological involvement in APS.RECENT FINDINGS: Although stroke is the most common cause of neurological manifestations in patients with APS, other neurological disorders have been increasingly associated with the disease, including cognitive dysfunction, headache, and epi...
Source: Epilepsy Curr - June 14, 2021 Category: Neurology Authors: Miguel Leal Rato Matilde Bandeira Vasco C Rom ão Diana Aguiar de Sousa Source Type: research
